HER-2/neu Ile655Val Polymorphism and the Risk of Breast Cancer A Case-Control Study

被引:16
|
作者
Siddig, Awatif [2 ]
Mohamed, Abdelrahim Osman [3 ]
Kamal, Hammed [4 ]
Awad, Salma [5 ]
Hassan, Ahmed H. [5 ]
Zilahi, Erika [6 ]
Al-Haj, Mohammed [6 ]
Bernsen, Roos [7 ]
Adem, Abdu [1 ]
机构
[1] United Arab Emirates Univ, Dept Pharmacol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[2] Sudan Univ Sci & Technol, Fac Med Lab Technol, Khartoum, Sudan
[3] Univ El Imam El Mahdi, Fac Med & Hlth Sci, Dept Biochem, Kosti, Sudan
[4] Univ Khartoum, Fac Med, Dept Surg, Khartoum, Sudan
[5] United Arab Emirates Univ, Dept Biochem, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[6] United Arab Emirates Univ, Dept Med Microbiol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[7] United Arab Emirates Univ, Dept Community Med, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
来源
RECENT ADVANCES IN CLINICAL ONCOLOGY | 2008年 / 1138卷
关键词
breast cancer; HER-2/neu; polymorphism; risk;
D O I
10.1196/annals.1414.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic alterations of the proto-oncogene human epidermal growth factor receptor (HER-2/neu) have been shown to induce malignant transformation and metastasis. Genotyping studies have addressed the association of codon 655 isoleucine to valine polymorphism located in the transmembrane coding region and the risk of breast cancer, but the results are inconsistent. In this study, we investigated the association of HER-2/neu Ile655Val polymorphism and the risk of breast cancer in a Sudanese population. In addition, the joint effects of HER-2/neu variants and our previously reported ESR1C325G polymorphism were tested for their association with breast cancer risk. Candidate single nucleotide polymorphism (SNP) in HER-2/neu Ile655Val [db SNP rs1136200] was genotyped in breast cancer patients and in healthy controls that were randomly selected from the same age group as the patients. Genotyping was performed using a high-throughput allelic discrimination method using real-time PCR, and data on clinical features and demographic details were collected. Associations between genotype and breast cancer were assessed by means of logistic regression. The prevalence of Val/Val genotype was similar in patients of breast cancer and control subjects. In comparison with the Ile/Ile genotype, the Ile/Val had a borderline significantly (P = 0.06) higher risk of breast cancer (OR = 2.95, 95% CI: 0.97-8.96). Regarding the genotypic and allelic frequencies stratified by age and menopausal status, there were no significant associations. A significantly higher risk of breast cancer was observed among homozygous carriers of ESR1325 CC genotype and heterozygous carriers of HER-2/neu655 Ile/Val genotype (P = 0.05; adjusted OR = 4.9, 95% Cl: 1.0-24). The association of HER-2/neu Ile655Val polymorphism and the risk of breast cancer was borderline significant with the heterozygous carrier being at higher risk. However, the frequency of different polymorphic variants varies with ethnicity. The results of this study suggest that a significant gene-gene interaction between ESR1325C (previously reported) and HER-2/neu Ile655Val variants may jointly contribute to a higher risk of breast cancer.
引用
收藏
页码:84 / 94
页数:11
相关论文
共 50 条
  • [41] BCL-2 (-938C>A), BAX (-248G>A), and HER2 Ile655Val Polymorphisms and Breast Cancer Risk in Indian Population
    Bhatt, Deepti
    Verma, Amit Kumar
    Bharti, Prahalad Singh
    Goyal, Yamini
    Alsahli, Mohammed A.
    Almatroudi, Ahmad
    Rahmani, Arshad Husain
    Almatroodi, Saleh
    Joshi, Prakash C.
    Alam, Mohammad Mahtab
    Ahmad, Irfan
    Zaman, Gaffar Sarwar
    Dev, Kapil
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [44] HER-2/neu diagnostics in breast cancer
    Carney, Walter P.
    Leitzel, Kim
    Ali, Suhail
    Neumann, Rainer
    Lipton, Allan
    BREAST CANCER RESEARCH, 2007, 9 (03)
  • [45] No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer
    Wang, LZ
    Habuchi, T
    Takahashi, T
    Kamoto, T
    Zuo, T
    Mitsumori, K
    Tsuchiya, N
    Sato, K
    Ogawa, O
    Kato, T
    INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (06) : 787 - 790
  • [46] Allellic HER-2 codon 655 polymorphism and the influence of plasma HER-2 levels in breast cancer Egyptian female patients
    Nassef A.A.
    Ibrahim N.Y.
    Comparative Clinical Pathology, 2014, 23 (3) : 613 - 617
  • [47] Evaluation of HER-2 NEU oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study
    Haffty, BG
    Brown, F
    Carter, D
    Flynn, S
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (04): : 751 - 757
  • [48] HER-2 therapy. HER-2/neu diagnostics in breast cancer
    Walter P Carney
    Kim Leitzel
    Suhail Ali
    Rainer Neumann
    Allan Lipton
    Breast Cancer Research, 9
  • [49] Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk
    Xie, DW
    Shu, XO
    Deng, ZL
    Wen, WQ
    Creek, KE
    Dai, Q
    Gao, YT
    Jin, F
    Zheng, W
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (05) : 412 - 417
  • [50] Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer
    Ameyaw, MM
    Tayeb, M
    Thornton, N
    Folayan, G
    Tariq, M
    Mobarek, A
    Evans, DAP
    Ofori-Adjei, D
    McLeod, HL
    JOURNAL OF HUMAN GENETICS, 2002, 47 (04) : 172 - 175